Article
Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.
Archives of toxicology - 1 Apr 2014
Liu Aiming, Krausz Kristopher W, Fang Zhong-Ze, Brocker Chad, Qu Aijuan, Gonzalez Frank J
Abstract excerpt
Gemfibrozil, a ligand of peroxisome proliferator-activated receptor α (PPARα), is one of the most widely prescribed anti-dyslipidemia fibrate drugs. Among the adverse reactions observed with gemfibrozil are alterations in liver function, cholestatic jaundice, and cholelithiasis. However, the mechanisms underlying these toxicities are poorly understood. In this study, wild-type and Ppara-null mice were dosed with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
